INBSIntelligent Bio Solutions Inc.
The schedule
- Thu15Oct
A crucial catalyst detailing broader enterprise adoption of INBS's fingerprint drug screening technology. Significant B2B wins can catapult the stock to $3.50, while delayed corporate uptake forces a markdown to $1.60.
- Fri13Nov
- Sat13Feb
The Q3 earnings print combined with the first look at FY27 fiscal targets. An affirmative growth trajectory combined with expense control allows a rebound to $2.50, while downward guidance resets share price to a precarious $1.00 level.
- Mon15Feb
With the Q1 2026 $6.86 million cash reserve likely depleted over the preceding trailing twelve months, this event evaluates the structural need for a secondary equity offering. A non-dilutive strategic lifeline achieves the $1.50 target, whereas a heavily discounted raise punishes shares to $0.60.
- Tue30Mar
The definitive look at INBS's total FY26 execution. A stabilization in operating margins and top-line validation helps the stock recapture the $1.00 mark, while an audit of widening losses drops valuation to $0.40.
- Wed12May
Past
- Fri14Aug
Actual outcome: Bull
Intelligent Bio Solutions reported in-line earnings with an EPS of -$1.80, but the stock surged 21.7% following a series of positive regulatory developments. Shares rallied after the company announced ISO recertification aligning with the FDA's Quality Management System Regulation. This milestone, alongside the recent completion of usability and method comparison studies, significantly strengthened its FDA 510(k) clearance strategy for its Intelligent Fingerprinting Drug Screening System, driving investor optimism.
- Fri10Jul
Actual outcome: Bear · $1.96 at outcome
Intelligent Bio Solutions' update on its at-the-market (ATM) equity line utilization sparked concerns over premature shareholder dilution, overshadowing progress on its mid-year commercial deployment. The market reacted negatively to the capital raise, driving the stock down 8.3% as investors prioritized the immediate dilutive impact over the company's non-invasive testing platform rollout.
An update on mid-year commercial deployment for Intelligent Bio Solutions' non-invasive testing platforms and potential utilization of at-the-market (ATM) equity lines. A constructive commercial narrative points to a $3.30 recovery, while premature dilution risks an adverse slide to $1.70.
- Wed13May
Actual outcome: Bear · $2.25 at outcome
Intelligent Bio Solutions reported in-line EPS of -$1.80 alongside strong fiscal third-quarter revenue growth of 46% year-over-year and gross margin expansion to 50.5%. However, the stock plunged 43.6% and breached the $2.50 bear floor, as the deep earnings losses failed to alleviate market concerns regarding the company's ongoing operating cash burn and long-term cash runway.
Market evaluation of Q1 FY26 financial execution, focusing specifically on operating cash burn against the recently bolstered $6.86 million cash balance. Favorable guidance targets a $4.50 level, while a failure to rein in the $4.48 million TTM operating cash flow deficit will likely trigger a retest of $2.50.